Oncotarget

Research Papers:

Long non-coding RNA NEAT1 overexpression is associated with poor prognosis in cancer patients: a systematic review and meta-analysis

Chao Yang _, Zhuo Li, Yajun Li, Rui Xu, Yongfeng Wang, Yu Tian and Wei Chen

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:2672-2680. https://doi.org/10.18632/oncotarget.13737

Metrics: PDF 4025 views  |   HTML 3871 views  |   ?  


Abstract

Chao Yang1, Zhuo Li1, Yajun Li2, Rui Xu3, Yongfeng Wang1, Yu Tian1, Wei Chen4

1Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an Medical University, Xi'an City, Shaanxi Province, China

2Department of Neurology, The First Affiliated Hospital of Xi'an Medical University, Xi'an City, Shaanxi Province, China

3Department of Clinical Research, The First Affiliated Hospital of Xi'an Medical University, Xi'an City, Shaanxi Province, China

4Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an City, Shaanxi Province, China

Correspondence to:

Chao Yang, email: [email protected]

Keywords: lncRNA, NEAT1, prognosis, cancer, meta-analysis

Received: October 09, 2016     Accepted: November 24, 2016     Published: December 01, 2016

ABSTRACT

Objectives: Long non-coding RNAs (lncRNAs) are playing important roles in cancer progression and metastasis. Recent studies have demonstrated that the lncRNA, nuclear paraspeckle assembly transcript 1 (NEAT1), was aberrantly up-regulated in various types of cancers and was reported to be associated with unfavorable prognosis in cancer patients. This study examined the relationship between NEAT1 and relevant clinical outcomes.

Results: A total of 1354 patients from 11 eligible studies were included in the meta-analysis. The results showed that high expression level of NEAT1 was significantly associated with shorter overall survival in cancer patients (hazard ratio (HR) = 1.53, 95% confidence interval (CI) = 1.36–1.71); in the subgroup analysis, the positive association was also found in patients with hepato-gastroenterol cancers (HR = 1.79, 95% CI = 1.48–2.16), non-small cell lung cancer (HR = 1.35, 95% CI = 1.04–1.76), ovarian cancer (HR = 1.41, 95% CI = 1.11–1.79) and other types of cancers (HR = 1.42, 95% CI = 1.11–1.81). The clinicopathological parameters analysis further showed that increased expression level of NEAT1 was positively correlated with larger tumor size (odds ratio (OR) = 1.74, 95% CI = 1.26–2.41), lymph node metastasis (OR = 2.29, 95% CI = 1.71–3.06), advanced TNM stage (OR = 3.60, 95% CI = 2.27–5.72), poor tumor differentiation (OR = 2.16, 95% CI = 1.58–2.93), distant metastasis (OR = 3.51, 95% CI = 1.75–7.01), and invasion depth (OR = 1.94, 95% CI = 1.36–2.75).

Materials and Methods: A comprehensive search was performed in Pubmed, Embase, Web of Science and CNKI databases, and eligible studies were included based on defined exclusion and inclusion criteria to perform meta-analysis.

Conclusions: The meta-analysis results from present study suggested that increased expression level of NEAT1 was associated with unfavorable prognosis and may serve as a predictive factor for clinicopathological features in various cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13737